Evidence map›Paper›PMID 32243668›Full record

ReviewThe oncologist2020

A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.

Humaid O Al-Shamsi, Waleed Alhazzani, Ahmad Alhuraiji, Eric A Coomes, Roy F Chemaly, Meshari Almuhanna, Robert A Wolff, Nuhad K Ibrahim, Melvin L K Chua, Sebastien J Hotte and 6 more

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04444401 (InterNaTional rEgistry oN Sars-cov-2posItiVe nEuroendocrine Neoplasm Patients), which is not on this map. Cited by 375 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
375citing papers in PubMed, 5 pooled it
54.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04444401 unknown statusnot on this map

InterNaTional rEgistry oN Sars-cov-2posItiVe nEuroendocrine Neoplasm Patients (INTENSIVE)

TypeobservationalSponsorEuropean Institute of OncologyRan2020 to 2023Enrolled50ConditionsNeuroendocrine Tumors, COVID-19
3 · Its place in the literature

Who cites it

375 citing papers in PubMed, 5 syntheses or guidelines pooled it, 716 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2026
    Article
  9. Article
  10. Article
  11. Influence of the COVID-19 pandemic on the incidence and mortality of primary spinal tumors in the United States: A SEER analysis.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article

315 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 8 countries.

Humaid O Al-ShamsiMedical Oncology Department, Alzahra Hospital Dubai, Dubai, United Arab Emirates.ORCID 0000-0003-3819-0500
Waleed AlhazzaniDepartment of Health Research Methods, Evidence, and Impact, Medicine, McMaster University, Hamilton, Ontario, Canada.
Ahmad AlhuraijiDepartment of Hematology, Kuwait Cancer Control Center, Kuwait.
Eric A CoomesDivision of Infectious Disease, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Roy F ChemalyDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Meshari AlmuhannaMin-Sheng General Hospital, Taoyuan City, Taiwan.
Robert A WolffDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nuhad K IbrahimDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Melvin L K ChuaDivisions of Radiation Oncology and Medical Sciences, National Cancer Center Singapore, Singapore.
Sebastien J HotteDepartment of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada.
Brandon M MeyersDepartment of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada.
Tarek ElfikiWindsor Regional Cancer Center, Windsor, Ontario, Canada.
Giuseppe CuriglianoDepartment of Oncology and Hemato-Oncology University of Milan, Milan, Italy.
Cathy EngVanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
Axel GrotheyWest Cancer Center, University of Tennessee, Memphis, Tennessee, USA.
Conghua XieDepartment of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China.
The University of Texas MD Anderson Cancer Center · USJuravinski Cancer Centre · CADuke-NUS Medical School · SGEmirates Foundation · AEKuwait Cancer Control Center · KWMcMaster University · CAMin Sheng General Hospital · TWUniversity of Milan · ITUniversity of Tennessee at Knoxville · USUniversity of Toronto · CAVanderbilt-Ingram Cancer CenterWestern University · CAWuhan University · CN

Funding

F. Hoffmann-La RocheKhalifa Foundation - Abu Dhabi - United Arab Emirates
6 · The paper itself

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) has rapidly spread globally since being identified as a public health emergency of major international concern and has now been declared a pandemic by the World Health Organization (WHO). In December 2019, an outbreak of atypical pneumonia, known as COVID-19, was identified in Wuhan, China. The newly identified zoonotic coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is characterized by rapid human-to-human transmission. Many cancer patients frequently visit the hospital for treatment and disease surveillance. They may be immunocompromised due to the underlying malignancy or anticancer therapy and are at higher risk of developing infections. Several factors increase the risk of infection, and cancer patients commonly have multiple risk factors. Cancer patients appear to have an estimated twofold increased risk of contracting SARS-CoV-2 than the general population. With the WHO declaring the novel coronavirus outbreak a pandemic, there is an urgent need to address the impact of such a pandemic on cancer patients. This include changes to resource allocation, clinical care, and the consent process during a pandemic. Currently and due to limited data, there are no international guidelines to address the management of cancer patients in any infectious pandemic. In this review, the potential challenges associated with managing cancer patients during the COVID-19 infection pandemic will be addressed, with suggestions of some practical approaches. IMPLICATIONS FOR PRACTICE: The main management strategies for treating cancer patients during the COVID-19 epidemic include clear communication and education about hand hygiene, infection control measures, high-risk exposure, and the signs and symptoms of COVID-19. Consideration of risk and benefit for active intervention in the cancer population must be individualized. Postponing elective surgery or adjuvant chemotherapy for cancer patients with low risk of progression should be considered on a case-by-case basis. Minimizing outpatient visits can help to mitigate exposure and possible further transmission. Telemedicine may be used to support patients to minimize number of visits and risk of exposure. More research is needed to better understand SARS-CoV-2 virology and epidemiology.

Indexed as

BetacoronavirusCoronavirus InfectionsCOVID-19Hand HygieneHumansInfection ControlInternational CooperationIntersectoral CollaborationMedical OncologyNeoplasmsPandemicsPatient CarePatient Education as TopicPneumonia, ViralResource AllocationSARS-CoV-2CoronavirusCOVID-19InfluenzaNeoplasmPandemicSARS-CoV-2

Identifiers

PMID32243668
PMCPMC7288661
OpenAlexW3014319236

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.